KESTRA MED TECHNOLOGIES LTD Stock Price, News & Analysis

Kestra Medical Technologies (Nasdaq: KMTS) appointed Timothy Moran as Chief Business Officer, effective November 3, 2025. In the role Moran will lead business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management.

Moran brings over 25 years in medtech, most recently serving as president and CEO at Avertix Medical where he led a launch of a first‑to‑market implantable cardiac device, and previously as CEO of Motus GI Holdings. Management expects Moran to support the company’s commercial ramp, advance payor and provider partnerships, and accelerate adoption of the Cardiac Recovery System and ASSURE® WCD.

Kestra Medical Technologies (Nasdaq: KMTS) announced its participation in the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis. The company will showcase its Cardiac Recovery System® (CRS) platform, featuring the ASSURE® Wearable Cardioverter Defibrillator at booth #920.

The CRS platform aims to enhance sudden cardiac death protection by combining protective measures with actionable insights during critical heart failure recovery phases. Visitors can experience hands-on demonstrations of the platform, which focuses on strengthening patient-provider connections and supporting vulnerable patients' recovery.

Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has appointed Dr. Elizabeth Kwo as an independent director to its board of directors. Dr. Kwo currently serves as Chief Commercial Officer of Everly Health and brings extensive experience in digital health platforms and data-driven care models.

Dr. Kwo's background includes roles as Deputy Chief Clinical Officer at Anthem, VP and GM of Provider Networks at American Well, and Entrepreneur in Residence at Harvard Medical School. She is board certified in preventive care and occupational medicine, holding degrees from Harvard Medical School (MD), Harvard School of Public Health (MPH), Harvard Business School (MBA), and Stanford University (BA).

Kestra Medical Technologies (Nasdaq: KMTS) reported strong Q1 FY26 financial results, with revenue reaching $19.4 million, a 52% increase year-over-year. The wearable medical device company saw significant growth with 4,205 prescriptions written for its ASSURE® system, up 51% from the previous year. Gross margin expanded to 45.7% from 32.9% year-over-year.

The company raised its FY26 revenue guidance to $88 million, representing 47% growth compared to FY25, up from previous guidance of $85 million. Despite strong top-line growth, Kestra reported a GAAP net loss of $25.8 million and held cash and equivalents of $201.2 million as of July 31, 2025.

Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its first quarter fiscal 2026 earnings release for Thursday, September 11. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results.

Interested participants can access the live and archived webcast through the "Events" section of Kestra's investor relations website and are advised to register at least 10 minutes before the call begins.

Biobeat Technologies has appointed Raymond W. Cohen as Chairman of the Board of Directors. The company, which develops wearable medical devices, has received FDA clearance for its innovative patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure.

Cohen brings over 40 years of life science industry experience, notably as co-founder and CEO of Axonics, which was acquired by Boston Scientific for $3.7 billion in 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch. Most recently, as chairman of SoniVie, he led its sale to Boston Scientific for $600 million in March 2025.

Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has been awarded the 2025 Top Workplaces Industry Award by Energage. The recognition is based on employee feedback through an engagement survey, highlighting Kestra's commitment to maintaining a people-first workplace culture.

CEO Brian Webster emphasized that this achievement reflects the team's dedication to their mission of advancing cardiac care through employee empowerment. The award positions Kestra as an employer of choice in the healthcare sector, with the company's workplace culture being specifically recognized for its focus on employee voice and engagement.

Kestra Medical Technologies (NASDAQ:KMTS), a wearable medical device company, reported strong Q4 and FY2025 results. Q4 revenue reached $17.2 million, up 71% year-over-year, while FY25 revenue hit $59.8 million, a 115% increase from FY24. The company's ASSURE® cardiac recovery system saw 13,193 prescriptions in FY25, up 72% from the previous year.

Gross margins significantly improved to 44.3% in Q4 FY25 from 13.9% in the prior year, and 40.5% for FY25 compared to 1.3% in FY24. Despite growth, the company reported a GAAP net loss of $51.1 million in Q4 and $113.8 million for FY25. Looking ahead, Kestra projects FY26 revenue of $85 million, representing 42% growth.

Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its fourth quarter and fiscal year 2025 financial results announcement for Tuesday, July 15, 2025. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can access both the live and archived webcast through the "Events" section of Kestra's investor relations website, with registration recommended at least 10 minutes before the call.